JAMA Study Maps Climate Disaster Exposure Across US Drug Manufacturing
- Nearly two-thirds of US drug production facilities are in areas with major disasters, according to a study in JAMA.
- The study analyzed FDA and FEMA databases, identifying 6,819 facilities in counties with disaster declarations from 2019 to 2024.
- Drug shortages highlight weaknesses in the pharmaceutical supply chain regarding climate-related events.
- Hurricanes were the most common disaster affecting these pharmaceutical facilities during this time.
14 Articles
14 Articles
How hurricanes, fires, and floods put drugs and medical supplies at risk - The Boston Globe
Nearly two-thirds of US drug production facilities are located in areas that have had a major disaster like a fire or hurricane in recent years, according to a new study published in the peer-reviewed journal JAMA.


U.S. Drug Plants Squarely in the Path of Hurricanes, Floods, and Fires
Disasters pose risks of disruptions to facilities active in all aspects of the supply chain
America’s fragile drug supply chain is extremely vulnerable to climate change
(Ars Technica) – Using data from the Food and Drug Administration, the researchers identified 10,861 drug facilities that were active for at least one year between 2019 and 2024. These facilities represent the array of manufacturing stages of a drug, from analyzing raw drug materials, manufacturing active ingredients, to packaging drug products. The researchers then looked at the county location of each of these facilities and whether any federa…
Coverage Details
Bias Distribution
- 60% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium